NASDAQ:ABUS Arbutus Biopharma Q4 2025 Earnings Results & Report $4.19 +0.08 (+1.95%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$4.22 +0.03 (+0.67%) As of 10/14/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Arbutus Biopharma reported Q4 2025 earnings on March 31, 2026. The company reported EPS of $0.87, while revenue was $179.13 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 31, 2026TimeBefore Market Opens Arbutus Biopharma EPS ResultsActual EPS$0.87Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersArbutus Biopharma Revenue ResultsActual Revenue$179.13 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsArbutus Biopharma's Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Arbutus Biopharma Q4 2025 Earnings FAQ Did Arbutus Biopharma beat earnings estimates for Q4 2025? Arbutus Biopharma (NASDAQ:ABUS) reported earnings of $0.87 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026. What was Arbutus Biopharma's revenue for Q4 2025? Arbutus Biopharma reported revenue of $179.13 million for Q4 2025. When is Arbutus Biopharma's next earnings date? Arbutus Biopharma's next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Arbutus Biopharma on the company's earnings history page. Arbutus Biopharma Earnings HeadlinesArbutus Biopharma (NASDAQ:ABUS) & Syndax Pharmaceuticals (NASDAQ:SNDX) Head-To-Head ComparisonOctober 13 at 5:01 AM | americanbankingnews.comContrasting Arbutus Biopharma (NASDAQ:ABUS) & Evaxion A/S (NASDAQ:EVAX)October 13 at 4:15 AM | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV CureOctober 8, 2026 | seekingalpha.comArbutus Announces Final Results of Its US$230 Million Modified 'Dutch Auction' Tender OfferOctober 2, 2026 | marketscreener.comMTranche Update on Arbutus Biopharma Corporation's Equity Buyback Plan announced on August 21, 2026.October 1, 2026 | marketscreener.comMSee More Arbutus Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email. Email Address About Arbutus BiopharmaArbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection and other viral diseases. The company’s research programs are based primarily on RNA interference (RNAi) therapeutics and small-molecule compounds designed to suppress viral replication and address the underlying biology of persistent infection. Arbutus’ HBV pipeline has included AB-729, an investigational subcutaneously administered RNAi therapeutic intended to reduce hepatitis B surface antigen, and AB-836, an investigational oral capsid inhibitor designed to interfere with HBV replication. The company also develops and licenses lipid nanoparticle delivery technology, which is intended to help transport nucleic acid medicines into cells. The company traces its history to Tekmira Pharmaceuticals, which combined with OnCore Biopharma in 2015 and adopted the Arbutus Biopharma name. Arbutus is headquartered in Warminster, Pennsylvania, and conducts research and clinical development through collaborations and studies involving international markets. Its leadership and development strategy have centered on advancing targeted therapies for chronic viral infections while leveraging its expertise in RNA medicines and drug-delivery technologies.View Arbutus Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
